- Curriculum Vitae
- Office hour
Born in Reggio Calabria on July 24, 1975; he lives in Parma. Married with two daughters.
Antonino Musolino is Associate Professor of Medical Oncology at the University of Parma, Italy. He is also Head of the Breast Unit, University Hospital of Parma.
His initial medical training was in Messina, Italy. Then, he moved to the University Hospital of Parma for specialist training in Cancer Medicine and, later, to the University Hospital of Padua for specialist training in Hematology. He also spent some time in London at the Royal Marsden Hospital (Gastrointestinal Cancer and Lymphoma Units, Head: Prof. David Cunningham). He achieved the PhD in Pathophysiology in 2009 at the University of Parma and the Master of Science in Epidemiology in 2017 at the University of Turin. His principal clinical and research interests are breast cancer, lymphomas, cancer epidemiology and pharmacogenetics.
Over the past 15 years he has become increasingly involved in clinical trials, pharmacogenetics, and epidemiological studies focusing on individualized treatments for HER2-positive breast cancer. He is currently Principal Investigator for several international multicenter breast cancer trials involving in particular targeted therapies. He publishes and lectures extensively. He was awarded the American Association for Cancer Research (AACR) Scholar-in-Training Award in recognition of promising cancer research at the 2007 AACR annual meeting and Elsevier Recognized Reviewer from 2016 to 2020.
Prof. Musolino is President of the Italian Oncology Group of Clinical Research (GOIRC), and member of the Breast International Group (BIG) task force on early clinical research.
Anno accademico di erogazione: 2021/2022
- Course year: 3 - First cycle degree (DM 270) - BIOMEDICAL LABORATORY TECHNIQUES - A.Y.: 2019/2020
Anno accademico di erogazione: 2020/2021
- Course year: 3 - First cycle degree (DM 270) - BIOMEDICAL LABORATORY TECHNIQUES - A.Y.: 2018/2019
Anno accademico di erogazione: 2019/2020
- Course year: 3 - First cycle degree (DM 270) - BIOMEDICAL LABORATORY TECHNIQUES - A.Y.: 2017/2018
Role of immunoglobulin G fragment C receptor polymorphism-mediatedantibody-dependant1. cellular cytotoxicity in colorectal cancer treated withcetuximab therapy. Pharmacogenomics J.Year: in stampaAuthor/s: MUSOLINO, Antonino, MISSALE, Gabriele, NERI, Tauro Maria
Is anti-Müllerian hormone a marker of ovarian reserve in young breast cancer patients receiving a GnRH analog during chemotherapy?Year: 2021Author/s: MUSOLINO, Antonino
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical TrialYear: 2021Author/s: MUSOLINO, Antonino
Year: 2021Author/s: PELLEGRINO, BENEDETTA, MUSOLINO, Antonino
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-1...Year: 2020Author/s: MICHELOTTI, Margherita, MUSOLINO, Antonino, PORPIGLIA, Marco, FABIANO, ANNALISA, GIORDANO, DOMIZIANA, DONADIO, ELEONORA MARIA, DEL MASTRO, GIANLUCA, LIVI, ALESSANDRO, MARCHETTI, PIERO